Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients

Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2

“…These findings show that HIV-1 and HIV-2 probably share similar INI resistance pathways and that INI resistance can develop in HIV-2 as in HIV-1 (49). The clinical efficacy of RAL in HIV-2 has been described in two case reports (19,33).…”

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

“…Our in vitro results are in keeping with two recent reports of short-term immunological and virological efficacy of INI-containing regimens in two heavily pretreated HIV-2- HIV-2 susceptibility to integrase inhibitors infected patients. 31,32 Due to the few number of active antiretroviral drugs available for the treatment of HIV-2-infected patients, this new class of antiretroviral drugs might represent a new therapeutic option for HIV-2-infected patients, which remains to be evaluated through multicentre trials. …”

HIV-1 Antiretroviral Drug Therapy

“…5) (Maignan et al 1998;Damond et al 2008;Shimura et al 2008;Van Baelen et al 2008;Garrido et al 2010;Singh et al 2010). In the cocrystal structure, the general architecture and amino acids within the active site of the foamy virus intasome are highly conserved with other retroviral integrases, as are the immediate surrounding interactions with InSTIs.…”